cjc-1295 with dac + ipamorelin No & CJC-1295 No DAC & Ipamorelin

In summary, Ipamorelin might be one of the mildest Growth Hormone Releasing Peptides but it is far from the weakest

The foundational characterization appeared in European Journal of Endocrinology in 1998, reporting selective agonism of the growth hormone secretagogue receptor type 1a (GHS-R1a) without significant elevation of ACTH, cortisol, prolactin, FSH, LH, or TSH, even at doses 200-fold above the GH-releasing ED50 in preclinical models

Order online, walk into any of 4,500+ LabCorp or Quest draw sites, and get results in 1-2 business days

Ipamorelin complements this by enhancing lipolysis, the process of breaking down stored fat into energy, while selectively stimulating the release of GH without disrupting hormonal balance

Shorter off-periods exist in practice, but the rationale supporting them is thin